Introduction {#s1}
============

Endoscopic submucosal dissection (ESD), as an endoscopic procedure, commonly used to treat gastric cancer and adenoma, was first reported in Japan and Korea in the late 1990s ([@B33]; [@B11]). ESD is performed using a variety of electrosurgical knives such as the insulated-tip or the triangle-tip models as to make gastrointestinal mucosal incisions and submucosal dissections ([@B35]; [@B53]; [@B36]). Unlike conventional techniques such as the strip biopsy or cap endoscopic mucosal resection (EMR), the en bloc resection can be achieved by ESD ([@B44]). Nowadays, it has gained popularity in Asian countries. With technical improvements and structured training, ESD is increasingly used in Western countries, and it is necessary to master the operation of this technology and vigorously promote it ([@B12]).

However, ESD, as a more complex and time-consuming procedure, has a higher risk of complications than classic EMR, mainly related to bleeding ([@B40]). Delayed bleeding occurs mostly within 24 h after ESD, and the incidence rate of delayed bleeding is approximately 5% ([@B48]). Although rare, it can develop severe complications such as delayed perforation, and blood will interfere with subsequent endoscopic procedures. Hence, prevention of bleeding after ESD has been an important clinical issue.

The bleeding was affected by pH levels, and the gastric pH may affect the efficiency of blood coagulation and platelet aggregation at the bleeding site ([@B14]; [@B3]). To neutralize pH level and prevent bleeding after ESD, there are some alternative medication options that include proton pump inhibitors (PPIs), histamine~2~-receptor antagonists (H~2~RAs), and so on. PPIs have been reported to be preferred than H~2~RAs treatment in some previous studies ([@B7]; [@B8]; [@B1]; [@B56]). Conversely, other studies showed that PPIs are not significantly effective than H~2~RAs ([@B39]; [@B22]; [@B25]; [@B49]). Vonoprazan (Takeda Pharmaceutical co., Tokyo, Japan) is a new potassium-competitive acid blocker (P-CAB). Its pharmaceutical advantages over PPIs include more rapid, stronger, and long-lasting inhibition of gastric acid secretion after administration ([@B27]; [@B46]). Moreover, vonoprazan effect is neither affected by CYP2C19 polymorphisms in its pharmacokinetics ([@B29]) nor affected by food intake ([@B45]; [@B42]). As a new class of acid-suppressing agents, it is expected to reduce the incidence of delayed bleeding after ESD better than conventional PPIs and serve as an alternative to PPIs ([@B19]; [@B27]; [@B46]).

The relative efficacy of PPIs, H~2~RAs, and the P-CAB (vonoprazan) has been assessed in randomized trials. However, the most appropriate management in preventing post-ESD bleeding remains controversial and to be defined. Moreover, the consumption of PPIs is especially high nowadays, and the overuse of PPIs has been an international concern ([@B32]). Hence, in our study, we performed a meta-analysis among H~2~RAs, PPIs, and vonoprazan to find out the best regimen to prevent bleeding after ESD. Despite the absence of head-to-head randomized control trials (RCTs), we conducted indirect comparison meta-analysis to estimate the efficacy of vonoprazan and H~2~RAs using PPI as the common comparator.

Methods {#s2}
=======

Data Sources and Searches {#s2_1}
-------------------------

The manuscript was drafted by the preferred reporting items for systematic reviews and meta-analyses statement ([@B37]). We searched three electronic databases: Pubmed, Cochrane Library, and Embase, from their inception date to 15th March 2019. There are no restrictions on abstracts and conference proceedings. We hand searched the relevant articles' references to extend the literature search. The following terms were used in the search, which were included in their titles, abstracts, or keyword lists: "endoscopic submucosal dissection," "ESD," "proton pump inhibitors," "PPI," "vonoprazan," "Potassium-Competitive Acid Blocker," "H2Ras." Only English publications were included.

Study Selection and Endpoints {#s2_2}
-----------------------------

The inclusion criteria used to select studies are predetermined. The eligible studies are as follows: 1) RCTs that compared the efficacy of H~2~RAs or vonoprazan against PPIs on prevention of bleeding after ESD, not during the operation procedure, 2) the study population are adults aging from 18 years old, 3) studies must report the data of delayed bleeding incidence after ESD, and 4) trials were excluded by not about the prevention of bleeding. We chose the delayed bleeding as the primary outcome. Two independent reviewers (Tiantian Zhang and Jiahao Li) retrieved all the potentially relevant articles. Any discrepancies between the two independent reviewers were resolved by a third investigator (Ning Wan).

Data Extraction and Quality Assessment {#s2_3}
--------------------------------------

The data were extracted by two reviewers (Tiantian Zhang and Jiahao Li) independently and included the name of the first author, year of publication, country, a total number of patients, age, sex of patients, therapeutic regimen, trial name, tumor location, tumor depths, tumor with scar, mean resected specimen, and histopathology. Each study was judged on the potential bias including low, high, and unclear as outlined in the Cochrane Collaboration Handbook ([@B17]).

Data Analysis {#s2_4}
-------------

In the absence of trials making head to head comparisons between H~2~RAs and vonoprazan, we then performed an adjusted indirect comparison using a common comparator---that is, PPIs---as described by the method of Bucher ([@B13]). When few direct studies are available and direct comparative studies have not been performed, indirect meta-analysis is used to estimate treatment effect and to strengthen the power of comparisons instead of replacing randomized trials of direct comparison ([@B6]; [@B47]; [@B9]; [@B43]). We performed traditional meta-analysis combining trials of H~2~RAs versus PPIs, vonoprazan versus PPIs, to obtain the estimated odds ratios (OR) with 95% confidence interval (CI). We calculated the I^2^ statistic and the Chi-square test to examine statistical heterogeneity among studies. If the heterogeneity results were considered to be statistically significant at a *P* value \< 0.1 and an I^2^ statistic \> 50%, the random-effects model would be much more appropriate. Otherwise, the fixed-effects model was used. To strengthen the reliability of these pooled results and explore possible reasons for heterogeneity, we performed a sensitivity analysis using the leave-one-out method and examined the publication bias by funnel plot and Egger's test. All tests were two-sided, and a P \< 0.05 was considered statistically significant ([@B16]; [@B10]; [@B34]). We used the STATA statistical software system v14.0 for statistical analysis.

Results {#s3}
=======

Literature Search {#s3_1}
-----------------

The process of study selection in our meta-analysis is shown in [**Figure 1**](#f1){ref-type="fig"}. Overall, the literature search identified 197 potentially relevant studies in our initial search. We excluded 130 articles for the following reasons: not involving prevention after ESD, review articles, duplicate articles, and retrospective studies. The remaining 67 articles were retrieved for further consideration. There were 51 articles that were excluded for not involving delayed bleeding and without sufficient data. Only 16 articles were included in the analysis including two conference abstracts ([@B28]; [@B51]; [@B39]; [@B22]; [@B49]; [@B25]; [@B30]; [@B21]; [@B23]; [@B15]; [@B20]; [@B54]).

![Preferred reporting items for systematic reviews and meta-analyses flowchart of the studies included in the meta-analysis.](fphar-10-01055-g001){#f1}

Study Characteristics and Qualities {#s3_2}
-----------------------------------

A total of 1,956 patients were enrolled in the meta-analysis including 16 trials. The characteristic of the 16 included articles is shown in [**Table 1**](#T1){ref-type="table"}. The quality of the randomized studies is shown in [**Table 2**](#T2){ref-type="table"}.

###### 

Clinical trials information.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                             Trial name      Country   Year            Total number of patients   Regimen                      No. of patients   Medication weeks   Age             Sex(male/female)   Tumor location (U/M/L)   Tumor location (body/antrum)   Tumor depths (m/sm)   Tumor with scar (+/-)   Mean resected specimen size/mm^2^+SD   Histopathology (adenoma/adenocarcinoma)
  --------------------------------- --------------- --------- --------------- -------------------------- ---------------------------- ----------------- ------------------ --------------- ------------------ ------------------------ ------------------------------ --------------------- ----------------------- -------------------------------------- -----------------------------------------
  Noriya Uedo                       NA              Japan     2007            143                        PPIs                         73                8                  68.1 ± 8.5      57/16              NA                       38/43                          NA                    12/69                   41.0 ± 16.1                            NA

  H2RAs                             70              8         65.7 ± 7.6      55/15                      NA                           30/48             NA                 9/69            40.5 ± 18.8        NA                                                                                                                                           

  Hye-Kyong Jeong                   NA              Korea     2007            164                        PPIs                         85                8                  62.9 ± 9.4      52/33              NA                       26/59                          NA                    NA                      31.1 ± 9.5                             71/14

  H2RAs                             79              8         63.5 ± 7.8      53/26                      NA                           22/57             NA                 NA              31.1 ± 10          59/20                                                                                                                                        

  Tomohiko Richard Ohya             NA              Japan     2010            60                         PPIs                         31                4                  65.4 ± 9.0      23/8               4/20/10                  NA                             33/1                  NA                      NA                                     NA

  H2RAs                             29              4         65.3 ± 8.0      21/8                       1/16/13                      NA                27/3               NA              NA                 NA                                                                                                                                           

  Hiroyuki Imaeda                   UMIN000001069   Japan     2011            123                        PPIs                         62                8                  68.4 ± 8.0      47/15              NA                       42/20                          59/2                  12/50                   NA                                     NA

  H2RAs                             61              8         67.6 ± 8.5      52/9                       NA                           36/25             61/0               8/53            NA                 NA                                                                                                                                           

  Toshihiko Tomita                  UMIN000001215   Japan     2012            156                        PPIs                         77                8                  70.4 ± 8.7      59/18              12/32/33                 NA                             66/11                 7/70                    43.8 ± 16.0                            NA

  H2RAs                             79              8         70.6 ± 9.5      59/20                      16/33/30                     NA                71/8               9/70            40.3 ± 15.6        NA                                                                                                                                           

  Jin Seok Jang ^†^                 NA              Korea     2012            77                         PPIs+Rebamipide              40                4                  NA              NA                 NA                       NA                             NA                    NA                      NA                                     NA

  H2RAs+Rebamipide                  37              4         NA              NA                         NA                           NA                NA                 NA              NA                 NA                                                                                                                                           

  Myung H. Noh ^†^                  NA              Korea     2013            190                        PPIs+Cytoprotective Agents   92                4                  NA              NA                 NA                       NA                             NA                    NA                      NA                                     NA

  H2RAs+Cytoprotective Agents       98              4         NA              NA                         NA                           NA                NA                 NA              NA                 NA                                                                                                                                           

  T. Kagawa                         UMIN000021010   Japan     2016            225                        PPIs+ Polaprezinc            150               8                  71.9 ± 9.1      91/59              20/33/97                 NA                             NA                    NA                      NA                                     26/124

  P-CAB (Vonoprazan)+ Polaprezinc   75              5         72.3 ± 8.4      52/23                      11/12/52                     NA                NA                 NA              NA                 10/65                                                                                                                                        

  Izumi Tsuchiya                    UMIN000017077   Japan     2017            80                         PPIs                         41                8                  74              30/11              5/15/19                  NA                             39/2                  NA                      NA                                     4/37

  P-CAB (Vonoprazan)                39              8         73              27/12                      9/13/19                      NA                39/0               NA              NA                 2/37                                                                                                                                         

  Akira Yamasaki                    NA              Japan     2017            167                        PPIs                         90                4                  70 (42--90)     66/24              11/44/35                 NA                             NA                    NA                      NA                                     6/84

  P-CAB (Vonoprazan)                77              4         71 (39--87)     54/23                      8/29/40                      NA                NA                 NA              NA                 2/75                                                                                                                                         

  Yohei Horikawa                    UMIN\           Japan     2018            115                        PPIs                         53                2 weeks            73 (60--86)     34/19              15/20/18                 NA                             46/7                  NA                      NA                                     NA
                                    000026391                                                                                                                                                                                                                                                                                                              

  P-CAB (Vonoprazan)                62              2 weeks   69.5 (47--84)   44/18                      12/24/26                     NA                55/7               NA              NA                 NA                                                                                                                                           

  Ai Hirai                          UMIN000016687   Japan     2018            149                        PPIs                         75                8                  69.9 ± 11.0     55/20              4/29/42                  NA                             71/4                  NA                      NA                                     7/68

  P-CAB (Vonoprazan)                74              8         73.2 ± 7.5      62/8                       9/27/41                      NA                60/14              NA              NA                 8/66                                                                                                                                         

  Kenta Hamada                      UMIN000017320   Japan     2018            139                        PPIs                         70                8                  70.1 ± 8.5      57/23              NA                       NA                             NA                    7/63                    38 ± 15                                NA

  P-CAB (Vonoprazan)                69              8         70.3 ± 6.8      51/18                      NA                           NA                NA                 6/63            38 ± 14            NA                                                                                                                                           

  Yasuaki Ishii                     MIN000016835    Japan     2018            53                         PPIs                         26                8                  70 (66--75.3)   22/3               14/10/2                  NA                             NA                    NA                      39.8 (26-80)                           NA

  P-CAB (Vonoprazan)                27              8         70 (65.3--75)   23/4                       12/10/5                      NA                NA                 NA              40.6 (30-54)       NA                                                                                                                                           

  Hiroyuki Komori                   UMIN000017386   Japan     2019            33                         PPIs                         15                4                  70.9 ± 8.8      11/4               2/8/5                    NA                             NA                    NA                      NA                                     NA

  P-CAB (Vonoprazan)                18              4         69 ± 9.3        13/5                       1/4/13                       NA                NA                 NA              NA                 NA                                                                                                                                           

  Takashi Ichida                    UMIN000019516   Japan     2019            82                         PPIs+Rebamipide              39                8                  73.9 (58--88)   34/5               4/18/17                  NA                             NA                    NA                      38.6 (21-66)                           14/25

  P-CAB (Vonoprazan)+Rebamipide     43              8         72.4 (52--89)   31/12                      7/12/24                      NA                NA                 NA              39.9 (18-66)       8/35                                                                                                                                         
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PPIs, proton pump inhibitors; H2RAs, histamine2-receptor antagonists; NA, not available; U/M/L, upper/middle/lower; m/sm, intramucosal cancer/submucosal invasive cancer; SD, standard deviation.

^†^abstract.

###### 

Quality of the randomized studies.

  Study (first author)   Random sequence generation   Allocation concealment   Blinding of participants and personnel   Blinding of outcome assessment   Incomplete outcome data   Selective reporting   Other sources of bias
  ---------------------- ---------------------------- ------------------------ ---------------------------------------- -------------------------------- ------------------------- --------------------- -----------------------
  [@B51]                 Low                          Low                      Low                                      Low                              Low                       Low                   Unclear
  [@B28]                 Low                          Low                      Low                                      Unclear                          Unclear                   Unclear               Unclear
  [@B39]                 Low                          Unclear                  Unclear                                  Unclear                          Unclear                   Low                   Unclear
  [@B22]                 Low                          Low                      Low                                      Low                              Low                       Low                   Unclear
  [@B49]                 Low                          Unclear                  Low                                      Low                              Low                       Low                   Unclear
  [@B25] ^†^             Low                          Unclear                  Unclear                                  Unclear                          Low                       Unclear               Unclear
  [@B38]                 Low                          Unclear                  Unclear                                  Unclear                          Low                       Unclear               Unclear
  [@B29]                 Unclear                      Unclear                  Low                                      Low                              Low                       Unclear               Unclear
  [@B54]                 Low                          Unclear                  Unclear                                  Low                              Low                       Low                   Unclear
  [@B50]                 Low                          Low                      Low                                      Unclear                          Unclear                   Low                   Unclear
  [@B18]                 Low                          Low                      High                                     High                             Unclear                   Low                   Unclear
  [@B15]                 Low                          Low                      High                                     Low                              Low                       Unclear               Unclear
  [@B23]                 Low                          Low                      High                                     Low                              Low                       Low                   Unclear
  [@B20]                 Low                          Unclear                  Unclear                                  Low                              Low                       Low                   Unclear
  [@B31]                 Low                          Unclear                  Unclear                                  Low                              Low                       Low                   Unclear
  [@B21]                 Low                          Low                      Low                                      Low                              Low                       Unclear               Unclear

^†^abstract.

Conventional Meta-Analysis {#s3_3}
--------------------------

There were seven studies with 913 patients about H~2~RAs versus PPIs. No significant statistical heterogeneity among trials was detected (I^2^ = 12.9%, P = 0.33). There was a slightly significant difference in delayed bleeding between the H~2~RAs and PPIs groups (OR: 1.83; 95% CI: 1.10 to 3.05, P = 0.02). However, this difference was not significant for 4 weeks (OR: 1.57; 95% CI: 0.52 to 4.68, P = 0.42). It was only for 8 weeks; PPIs were superior to H~2~RAs in delayed bleeding (OR: 1.91; 95% CI: 1.08 to 3.40, P = 0.028). Compared with the OR of PPIs monotherapy, the OR of H~2~RAs monotherapy was 1.66 (95% CI: 0.96 to 2.88). When combined with protective agents, the OR increased to 3.24 (95% CI: 0.77 to 13.66) (see [**Figures 2**](#f2){ref-type="fig"}--[**4**](#f4){ref-type="fig"}).

![The meta-analysis of delayed bleeding for H~2~RAs with PPIs.](fphar-10-01055-g002){#f2}

![The medication duration subgroup meta-analysis of delayed bleeding for H~2~RAs with PPIs.](fphar-10-01055-g003){#f3}

![The medication regimen subgroup meta-analysis of delayed bleeding for H~2~RAs with PPIs.](fphar-10-01055-g004){#f4}

As for the nine trials of vonoprazan versus PPIs including 1,043 patients, a significant difference in delayed bleeding (OR: 0.46; 95% CI: 0.25 to 0.86, P = 0.015) was found in vonoprazan versus PPIs. In the subgroup analysis, there existed a significant difference in delayed bleeding when vonoprazan was combined with mucosal protective antiulcer drug in treatment compared with PPI combination therapy (OR: 0.18; 95% CI: 0.04 to 0.69, P = 0.013), while the OR was 0.70 for vonoprazan monotherapy (95% CI: 0.33 to 1.47). Additionally, vonoprazan showed better efficacy in delayed bleeding in 8 weeks' medication than PPIs (OR: 0.44; 95% CI: 0.21 to 0.92) (see [**Figures 5**](#f5){ref-type="fig"}--[**7**](#f7){ref-type="fig"}).

![The meta-analysis of delayed bleeding for vonoprazan with PPIs.](fphar-10-01055-g005){#f5}

![The medication duration subgroup meta-analysis of delayed bleeding for vonoprazan with PPIs.](fphar-10-01055-g006){#f6}

![The medication regimen subgroup meta-analysis of delayed bleeding for vonoprazan with PPIs.](fphar-10-01055-g007){#f7}

Adjusted Indirect Comparison Based on Common Controls {#s3_4}
-----------------------------------------------------

The adjusted indirect comparison of delayed bleeding was performed for vonoprazan and H~2~RAs using PPIs as the comparator. This demonstrated that vonoprazan was superior to H~2~RAs (OR: 0.30, 95% CI: 0.12 to 0.74). The same trend was found in the subgroup analysis of vonoprazan compared with H~2~RAs. The OR between vonoprazan and H~2~RAs of 8 weeks' medication duration was 0.29 (95% CI: 0.10 to 0.86). The OR between vonoprazan and H~2~RAs in a combination regimen with protective agents was 0.061 (95% CI: 0.006 to 0.458).

Sensitivity Analysis {#s3_5}
--------------------

The results of leave-one-out sensitivity analysis indicated that no individual studies significantly influenced the OR (see [**Figure 8**](#f8){ref-type="fig"}). Based on the funnel plot and Egger's test, no significant publication bias was found that may confirm the stability of our results (see [**Figures 9**](#f9){ref-type="fig"}--[**12**](#f12){ref-type="fig"}). The *P* values for Egger's test were 0.810 for H~2~RAs with PPIs and 0.209 for vonoprazan with PPIs.

![The leave-one-out sensitivity analysis of preventing bleeding after ESD per medication option.](fphar-10-01055-g008){#f8}

![Funnel plot of the standard error of publication bias for H~2~RAs with PPIs.](fphar-10-01055-g009){#f9}

![Egger's plot of the standard error of publication bias for H~2~RAs with PPIs.](fphar-10-01055-g010){#f10}

![Funnel plot of the standard error of publication bias for vonoprazan with PPIs.](fphar-10-01055-g011){#f11}

![Egger's plot of the standard error of publication bias for vonoprazan with PPIs.](fphar-10-01055-g012){#f12}

Discussion {#s4}
==========

Based on the traditional meta-analysis, PPIs was inferior to vonoprazan in the prevention of bleeding after ESD, while it was superior to H~2~RAs. In the result of indirect comparison meta-analysis by using PPIs as an intermediary, there was a significant decrease in delayed bleeding in vonoprazan versus H~2~RAs. In the subgroup analysis, the superiority of PPIs than H~2~RAs was more obvious in 8 weeks of medication duration than 4 weeks. Meanwhile, the significant effect of vonoprazan versus PPIs was more obvious under the situation of combination therapy than monotherapy and 8 weeks medication duration than 4 weeks.

The rapid promotion of ESD calls for quality improvement and precise management in preventing post-ESD bleeding. To our knowledge, we represented the first step at finding out a more appropriate management system for delayed bleeding prevention including choice of drug, combination of medication, and medication duration by conducting both direct and indirect meta-analysis.

According to our research results, either vonoprazan or PPIs may have better efficacy in preventing post-ESD bleeding in 8 weeks of medication duration than 4 weeks. Additionally, vonoprazan--mucosal protective antiulcer drugs regimen was better than PPIs--mucosal protective antiulcer drugs. The probable explanation was that it may exist as a much stronger synergistic effect between the vonoprazan and mucosal protective antiulcer drugs than PPIs. Therefore, we recommended that the patients who have a high risk of bleeding including long operation time, large resection range, deeper tumor location, and the combination treatment with drugs of potential bleeding take vonoprazan--mucosal protective antiulcer drugs for 8 weeks. However, for patients under low risk of bleeding, shorter duration may be a better choice, taking both cost and adverse events into consideration.

In one previous meta-analysis ([@B55]), it indicated that PPIs were superior to H~2~RAs for the prevention of delayed bleeding. However, the author mixed the EMR and ESD studies to assess the delayed bleeding in the ESD subgroup analysis and may lead to some controversial results. Instead, our study focused on ESD specifically and compared the prevention efficacy of PPIs with H~2~RAs and vonoprazan for delaying the bleeding after ESD. In the medication duration of H~2~RA and PPI subgroup analysis, our results were consistent with the former study that revealed that PPIs exerted a better influence in 8 weeks' medication duration than in 4 weeks. The reason may be that the actions of H~2~RAs are significantly faster than those of PPIs ([@B2]; [@B52]). A recent meta-analysis compared the rate of healing of ulcers caused by ESD and post-ESD delayed bleeding between vonoprazan and PPIs ([@B26]). However, since three eligible studies were not included, the research concluded that no difference was found between vonoprazan and PPIs.

There were several limitations associated with our study. Firstly, we should not neglect the heterogeneity among different clinical trials. In our study, the regimens of the RCTs were diverse from each other. As the multivariate analysis indicated, the scar in the tumor as well as the size of the tumor, and the endoscopists' skill, were independent predictors for bleeding ([@B51]; [@B5]; [@B24]; [@B41]). All these factors may have an impact on clinical results. Further studies with a larger number of patients are required to clarify the association between the comorbidities and complications after ESD. Secondly, we could not analyze the safety of the treatments without enough adverse events data. Thirdly, there may exist a population bias in our study. All trials included in our research were implemented in Asia, and only one evidence was from Italy ([@B4]). Therefore, the generalization of results should be taken in caution. On the other hand, the most appropriate drug administration time (before ESD or after ESD) and method (orally or intravenously) of PPIs still remained controversial. Meanwhile, even vonoprazan and PPI were preferable in efficacy; it may not be optimal choices in terms of their high cost compared with H~2~RAs. Therefore, more high-quality researches including cost-effectiveness analysis should be conducted to evaluate these issues and give some further guidance for clinical application.

In conclusion, our results show better effects of vonoprazan over PPIs over H~2~RAs in preventing bleeding after ESD. When vonoprazan was combined with mucosal protective antiulcer drug in treatment or used in 8 weeks of medication, the efficacy may be even better. So, as for the high-bleeding risk patients, it was recommended to take vonoprazan combination therapy or take vonoprazan for 8 weeks. However, due to the lack of adverse events data, more studies are needed on safety profiles of the previously discussed options and should be conducted on the Western population for the generalization of our results.
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